Document is current
Any future updates will be listed below
-
Authors
Unterleiter, Tom
Shariff, Maya https://orcid.org/0000-0002-3963-1059
Rückert, Michael https://orcid.org/0000-0002-9605-4841
Winterling, Lena
Ruspeckhofer, Laura
Weissmann, Thomas https://orcid.org/0000-0002-1443-5422
Putz, Florian https://orcid.org/0000-0003-3966-2872
Fietkau, Rainer
Bert, Christoph https://orcid.org/0000-0002-8539-6600
Gaipl, Udo S. https://orcid.org/0000-0001-6375-5476
Deloch, Lisa https://orcid.org/0000-0002-5577-2302
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 26 June 2025
Accepted: 12 November 2025
First Online: 22 November 2025
Declarations
:
: RF received funding from Fresenius Nutrition, Merck Oncology, Merck Serono, Astra-Zeneca, MSD, Novocure, Siemens; has lecture activities for Lilly, Roche Pharma, Brainlab, Fresenius Nutrition, Sennewald GmbH, Merck Oncology, Merck Serono, Novocure, MSD, AstraZeneca; and has done consulting for Lilly, Roche Pharma, Fresenius Nutrition, Sennewald GmbH, Merck Oncology, Merck Serono, MSD, Bristol Myers Squibb, AstraZeneca.
